-
Subject Areas on Research
-
"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
-
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.
-
A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
-
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
-
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
-
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).
-
A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
-
AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
-
AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3-Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML).
-
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
-
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
-
Chemokine CXCL1 enhances inflammatory pain and increases NMDA receptor activity and COX-2 expression in spinal cord neurons via activation of CXCR2.
-
Cholecystokinin action on layer 6b neurons in somatosensory cortex.
-
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
-
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
-
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
-
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
-
Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.
-
Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.
-
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
-
Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
-
Domain-specific effector interactions within the central cavity of human adult hemoglobin in solution and in porous sol-gel matrices: evidence for long-range communication pathways.
-
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
-
Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis.
-
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
-
Evaluation of fish models of soluble epoxide hydrolase inhibition.
-
Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
-
Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.
-
Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.
-
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
-
Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
-
N-3-pyridylmethyl-N'-p-nitrophenylurea ocular toxicity in man and rabbits.
-
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.
-
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
-
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
-
Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells.
-
Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.
-
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
-
Problems with the randomized discontinuation design.
-
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.
-
Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
-
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
-
Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion.
-
Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
-
Regulation of intestinal cholecystokinin and somatostatin mRNA by bombesin in rats.
-
Releasing the block: setting differentiation free with mutant IDH inhibitors.
-
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
-
STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
-
Sex-Dependent Glial Signaling in Pathological Pain: Distinct Roles of Spinal Microglia and Astrocytes.
-
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
-
Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.
-
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
-
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
-
Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
-
Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.
-
Treatment options in renal cell carcinoma: past, present and future.
-
Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
-
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
-
Keywords of People
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Pang, Herbert,
Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics,
Biostatistics & Bioinformatics
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Biomedical Engineering
-
Yan, Hai,
Adjunct Professor of Pathology,
Pathology